Loss or Silencing of the PHD1 Prolyl Hydroxylase Protects Livers of Mice Against Ischemia/Reperfusion Injury
Background & Aims
Liver ischemia/reperfusion (I/R) injury is a frequent cause of organ dysfunction. Loss of the oxygen sensor prolyl hydroxylase domain enzyme 1 (PHD1) causes tolerance of skeletal muscle to hypoxia. We assessed whether loss or short-term silencing of PHD1 could likewise induce hypoxia tolerance in hepatocytes and protect them against hepatic I/R damage.
Methods
Hepatic ischemia was induced in mice by clamping of the portal vessels of the left lateral liver lobe; 90 minutes later livers were reperfused for 8 hours for I/R experiments. Hepatocyte damage following ischemia or I/R was investigated in PHD1-deficient (PHD1−/−) and wild-type mice or following short hairpin RNA-mediated short-term inhibition of PHD1 in vivo.
Results
PHD1−/− livers were largely protected against acute ischemia or I/R injury. Among mice subjected to hepatic I/R followed by surgical resection of all nonischemic liver lobes, more than half of wild-type mice succumbed, whereas all PHD1−/− mice survived. Also, short-term inhibition of PHD1 through RNA interference−mediated silencing provided protection against I/R. Knockdown of PHD1 also induced hypoxia tolerance of hepatocytes in vitro. Mechanistically, loss of PHD1 decreased production of oxidative stress, which likely relates to a decrease in oxygen consumption as a result of a reprogramming of hepatocellular metabolism.
Conclusions
Loss of PHD1 provided tolerance of hepatocytes to acute hypoxia and protected them against I/R-damage. Short-term inhibition of PHD1 is a novel therapeutic approach to reducing or preventing I/R-induced liver injury.
Keywords: PHD1, Prolyl Hydroxylase, Ischemia/Reperfusion
Abbreviations used in this paper: ALT, alanine aminotransferase, HIF, hypoxia inducible factor, I/R, ischemia/reperfusion, 8-OHdG, 8-hydroxy-2′-deoxyguanosine, PDC, pyruvate dehydrogenase enzyme complex, PDK, pyruvate dehydrogenase kinase, PHD, prolyl hydroxylase domain, ROS, reactive oxygen species, WT, wild-type
To access this article, please choose from the options below
Conflicts of interest The authors disclose the following: P.R. and P.M. are scientific co-founders of ReOx Ltd, a University spin-out company that seeks to develop HIF Hydroxylase Inhibitors. The remaining authors disclose no conflicts.
Funding Supported by the Emmy Noether-Program of the Deutsche Forschungsgemeinschaft (to MS), by grant IUAP06/30 from the Federal Government Belgium, and by grants FWO G.0265 and FWO G.0387 from the Flanders Research Foundation, Belgium.
PII: S0016-5085(09)01752-1
doi:10.1053/j.gastro.2009.09.057
© 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

